Trapencaine

CAS No. 76629-91-9

Trapencaine( —— )

Catalog No. M36243 CAS No. 76629-91-9

Trapencaine is a newly synthesized carbamate type local anesthetic that induces conformational changes in sodium channels on hypertrophic cell membranes.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 126 In Stock
10MG 187 In Stock
25MG 307 In Stock
50MG 421 In Stock
100MG 570 In Stock
200MG 768 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Trapencaine
  • Note
    Research use only, not for human use.
  • Brief Description
    Trapencaine is a newly synthesized carbamate type local anesthetic that induces conformational changes in sodium channels on hypertrophic cell membranes.
  • Description
    Trapencaine is a newly synthesized carbamate type local anesthetic that induces conformational changes in sodium channels on hypertrophic cell membranes.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    Sodium Channel
  • Recptor
    Sodium Channel
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    76629-91-9
  • Formula Weight
    374.52
  • Molecular Formula
    C22H34N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O(C(NC1=CC(OCCCCC)=CC=C1)=O)C2C(CCCC2)N3CCCC3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Nicainoprol

    A sodium channels blocker, adrenergic receptor antagonist and class 1 antiarrhythmic agent.

  • Zoniporide hydrochlo...

    Zoniporide hydrochloride is a selective inhibitor of NHE-1 with IC50 of 14 nM which is >150-fold selectivity versus other NHE isoforms. Zoniporide hydrochloride shows an IC50 of 59 nM for NHE-1-dependent swelling of human platelets.

  • Eslicarbazepine

    Eslicarbazepine can be used for adjunctive therapy for adults with partial-onset seizures.